加载中...

MedXY News - clinical trial

MedXY AI/MedXY News/Tag: clinical trial

MedXY News

EnglishTag

clinical trial

170 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Early Enteral Nutrition Reduces Postoperative Complications in High-Risk Pancreatoduodenectomy Patients

Early Enteral Nutrition Reduces Postoperative Complications in High-Risk Pancreatoduodenectomy Patients

The NUTRIWHI trial demonstrates that early enteral nutrition via nasojejunal tube significantly reduces complication burden in nutritionally high-risk patients after pancreatoduodenectomy compared to oral nutrition alone.

Section: GastroenterologyApr 27, 2026

Five-Year Ublituximab Treatment Shows Sustained Benefits in Relapsing Multiple Sclerosis: ULTIMATE Extension Study

Five-Year Ublituximab Treatment Shows Sustained Benefits in Relapsing Multiple Sclerosis: ULTIMATE Extension Study

Long-term data from the ULTIMATE open-label extension study demonstrates sustained efficacy and safety of ublituximab in relapsing multiple sclerosis over five years, with significant reductions in relapse rates and disability progression c

Section: Allergy & ImmunologyApr 23, 2026

PrimeC Combination Therapy Shows Potential to Slow Functional Decline in Amyotrophic Lateral Sclerosis: Insights from the PARADIGM Trial

PrimeC Combination Therapy Shows Potential to Slow Functional Decline in Amyotrophic Lateral Sclerosis: Insights from the PARADIGM Trial

The Phase 2b PARADIGM trial demonstrates that PrimeC—a novel combination of celecoxib and ciprofloxacin—is safe and significantly slows functional decline in ALS patients over 18 months, offering new hope for multi-target neuroprotective st

Section: NeurologyMar 30, 2026

Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial

Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial

This phase 2 trial demonstrates that memantine, an NMDA receptor antagonist, significantly reduces premature atrial contractions (PACs) and nonsustained atrial tachycardia burden, suggesting the cardiac glutamatergic system as a novel thera

Section: CardiologyMar 20, 2026

Artificial Intelligence in Gastric Endoscopy: Decoding the Findings of a Landmark Multicenter Randomized Controlled Trial

Artificial Intelligence in Gastric Endoscopy: Decoding the Findings of a Landmark Multicenter Randomized Controlled Trial

A large-scale multicenter RCT investigating AI-assisted gastric neoplasm detection found no significant improvement in pathologically confirmed detection rates but demonstrated significant reductions in procedural blind spots and benefits f

Section: Clinical UpdatesMar 12, 2026

Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial

Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial

The APERITIF trial explored adding low-dose rivaroxaban to standard dual antiplatelet therapy to prevent heart clots after an anterior heart attack. While the addition did not significantly reduce thrombus formation, it did increase minor b

Section: CardiologyMar 10, 2026

Precision Rehabilitation for Chronic Stroke: Validating Targeted Ipsilesional Arm Training to Enhance Functional Capacity

Precision Rehabilitation for Chronic Stroke: Validating Targeted Ipsilesional Arm Training to Enhance Functional Capacity

A pivotal randomized clinical trial reveals that targeted training of the ipsilesional arm in chronic stroke patients with severe hemiparesis significantly improves motor speed and hand function, with benefits sustained for six months.

Section: Clinical UpdatesMar 10, 2026

Antiepileptogenesis After Stroke: Assessing the Impact of Eslicarbazepine Acetate on Seizure Prevention

Antiepileptogenesis After Stroke: Assessing the Impact of Eslicarbazepine Acetate on Seizure Prevention

This article examines a Phase 2a trial investigating eslicarbazepine acetate for preventing post-stroke epilepsy. While the primary endpoint was not met due to recruitment challenges, the study provides a critical framework for future antie

Section: NeurologyMar 7, 2026

Antenatal Prebiotic Supplementation Fails to Prevent Atopic Dermatitis in High-Risk Infants: Insights from the PREGRALL Trial

Antenatal Prebiotic Supplementation Fails to Prevent Atopic Dermatitis in High-Risk Infants: Insights from the PREGRALL Trial

The multicenter PREGRALL trial demonstrates that maternal intake of galacto-oligosaccharide/inulin prebiotics from mid-gestation does not reduce the incidence of atopic dermatitis or allergic sensitization in high-risk infants by age one, c

Section: Allergy & ImmunologyMar 5, 2026

Evaluating Low-Dose Lithium Carbonate for the Management of Mild Cognitive Impairment: A 2-Year Randomized Pilot Study

Evaluating Low-Dose Lithium Carbonate for the Management of Mild Cognitive Impairment: A 2-Year Randomized Pilot Study

This pilot randomized clinical trial investigated low-dose lithium for Mild Cognitive Impairment (MCI). While primary outcomes regarding cognition and neuroimaging were not statistically significant, the study established the intervention’s

Section: NeurologyMar 3, 2026

Diacerein Fails to Outperform Placebo in Patients with Inflammatory Phenotype Knee Osteoarthritis

Diacerein Fails to Outperform Placebo in Patients with Inflammatory Phenotype Knee Osteoarthritis

A multicenter randomized trial shows diacerein provides no clinical benefit over placebo for knee pain in patients with MRI-confirmed inflammation, despite its theoretical role as an IL-1β blocker.

Section: newsMar 3, 2026

Brief Psychological Intervention for Personality Disorder Shows No Benefit: Insights from the SPS Trial

Brief Psychological Intervention for Personality Disorder Shows No Benefit: Insights from the SPS Trial

A multicentre RCT in England demonstrates that a 10-session brief psychological intervention offers no significant improvement in social functioning or cost-effectiveness for individuals with probable personality disorder, reinforcing the n

Section: newsMar 2, 2026

Giving Kids a Voice: How Patient-Reported Outcome Measures are Transforming Pediatric Specialty Care

Giving Kids a Voice: How Patient-Reported Outcome Measures are Transforming Pediatric Specialty Care

Explore how standardized health questionnaires empower children and parents to share their priorities in medical settings, leading to more personalized and effective treatment plans.

Section: newsFeb 26, 2026

Long-Term Benfotiamine Treatment Fails to Improve Diabetic Polyneuropathy: Insights from the BOND Randomized Controlled Trial

Long-Term Benfotiamine Treatment Fails to Improve Diabetic Polyneuropathy: Insights from the BOND Randomized Controlled Trial

The 12-month BOND study found that high-dose benfotiamine (600 mg daily) did not significantly improve corneal nerve fiber length or other neurophysiological markers in patients with type 2 diabetes and symptomatic polyneuropathy, despite s

Section: Diabetes & EndocrinologyFeb 23, 2026

Telesurgery Breaks the Distance Barrier: Landmark RCT Confirms Non-Inferiority to Local Robotic Urology

Telesurgery Breaks the Distance Barrier: Landmark RCT Confirms Non-Inferiority to Local Robotic Urology

A multicentre randomized controlled trial demonstrates that robotic telesurgery over distances up to 2800 km is non-inferior to local surgery for urological procedures, maintaining high success rates, low latency, and equivalent safety prof

Section: AIFeb 26, 2026

Injectable vs. Sublingual Buprenorphine: Shaping the Future of Emergency OUD Care

Injectable vs. Sublingual Buprenorphine: Shaping the Future of Emergency OUD Care

The ED INNOVATION trial reveals that 7-day extended-release injectable buprenorphine is safe and as effective as sublingual formulations for treatment engagement, offering significant benefits in craving reduction and patient satisfaction e

Section: Emergency MedicineFeb 22, 2026

$Beyond Antihistamines: Dupilumab Emerges as a Potent Strategy for Refractory Chronic Spontaneous Urticaria$

Beyond Antihistamines: Dupilumab Emerges as a Potent Strategy for Refractory Chronic Spontaneous Urticaria

The Phase 3 LIBERTY-CSU CUPID trials demonstrate that dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria uncontrolled by antihistamines, providing a crucial new therapeutic option for those who are

Section: Allergy & ImmunologyFeb 20, 2026

Long-Term Parity in Adhesiolysis: 5-Year Results from the LASSO Randomized Trial Challenge Laparoscopic Superiority

Long-Term Parity in Adhesiolysis: 5-Year Results from the LASSO Randomized Trial Challenge Laparoscopic Superiority

The 5-year follow-up of the LASSO randomized clinical trial demonstrates that while laparoscopic adhesiolysis offers short-term recovery benefits, it provides no significant long-term advantage over open surgery regarding SBO recurrence, in

Section: GastroenterologyFeb 20, 2026

Automated Oxygen Control vs. Manual Care: Large-Scale Trial Finds No Difference in Clinical Outcomes for Extremely Preterm Infants

Automated Oxygen Control vs. Manual Care: Large-Scale Trial Finds No Difference in Clinical Outcomes for Extremely Preterm Infants

A multicenter randomized trial of 1,082 extremely preterm infants found that automated FiO2 control did not significantly reduce death or major morbidities compared to manual titration, though it remains a safe labor-saving tool for neonata

Section: Critical CareFeb 15, 2026

Metopimazine Mesylate (NG101) in Gastroparesis: Navigating the Complexities of Nausea Management and Trial Endpoints

Metopimazine Mesylate (NG101) in Gastroparesis: Navigating the Complexities of Nausea Management and Trial Endpoints

This Phase 2 trial of NG101 for gastroparesis did not meet its primary endpoint for nausea severity reduction but showed significant global improvement in patient-reported outcomes and a favorable safety profile, particularly in idiopathic

Section: GastroenterologyFeb 4, 2026

Prev 1 2 3 9 Next